EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China

Zhandong Qiu iD, Fang Xu, Mengyao Zhang, Xixi Yang, Yan Han, Dawei Li, Liang Liu, Jia Chen, Lehong Gao, Qing Xue, Yue Hou, Ying Sun und 7 weitere

CNS Neuroscience & Therapeutics · 2025-02 · 31 (2)

DOI: 10.1111/cns.70237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 20.02.2025. Verfasst von Zhandong Qiu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders, Beijing, China. Hauptthemen laut MEDLINE: Glutamate Decarboxylase, Autoantibodies, Autoimmune Diseases of the Nervous System, Autoimmunity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: parallel project 5 of Beijing Research Ward Excellence Program,BRWEP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore the clinical phenotypes, characteristics, immunotherapy response, and outcomes of glutamic acid decarboxylase‐65 (GAD65) neurological autoimmunity.

Methods

We performed a retrospective review of patients diagnosed with GAD65 neurological autoimmunity in the Department of Neurology at Xuanwu Hospital over the past 6 years (2017–2023). The clinical and laboratory data, imaging, therapeutic response, and long‐term prognosis of those patients were collected and analyzed.

Results

Among the 37 patients displaying significant neurological impairment, there were 14 males (37.8%) and 23 females (62.2%), with a median age of onset of 41.5 (25–59) years and a median interval of 9 (1.5–36) months from onset to a definitive diagnosis. Clinical phenotypes included epilepsy (15, 40.5%), limbic encephalitis (7, 18.9%), brainstem dysfunction (2, 5.4%), parkinsonism (2, 5.4%), peripheral neuropathy (3, 8.1%), cerebellar ataxia (1, 2.7%), and overlap syndromes (7, 18.9%). Out of 36 patients who received immunotherapy, the median time from onset to initiation of immunotherapy was 8.5 (1.5–37.5) months. Four cases were lost to follow‐up, leaving a median follow‐up period of 20.5 (16–37.25) months among the remaining 32 patients. Most patients (26, 81.3%) responded positively to immunotherapy, with some showing mild improvement or no response. Some patients showed inadequate responses to treatments such as mycophenolate mofetil (MMF), but significant improvement is observed after switching to rituximab (RTX). The relationship between the timing of initiating immunotherapy and prognosis by Spearman's rank correlation only showed weak correlation.

Conclusion

The clinical spectrum of GAD65 neurological autoimmunity appeared highly diverse. Immunotherapy can benefit the majority of patients, and early treatment appeared to be associated with good prognosis. RTX may be more effective than MMF; however, this requires more rigorous prospective studies to explore.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glutamate DecarboxylaseAutoantibodiesAutoimmune Diseases of the Nervous SystemAutoimmunityHumansMaleFemaleAdultMiddle AgedRetrospective StudiesChinaImmunotherapy

Stichwörter der Autor:innen

epilepsyglutamic acid decarboxylase‐65immunotherapylimbic encephalitisrituximab

Substanzen

Glutamate DecarboxylaseAutoantibodies

Autor:innen und Institutionen

  • Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders, Beijing, China.

ORCID-Profile: Zhandong Qiu

Förderung

  • parallel project 5 of Beijing Research Ward Excellence Program,BRWEP

Zitieren

APA

Qiu, Z., Xu, F., Zhang, M., Yang, X., Han, Y., Li, D., Liu, L., Chen, J., Gao, L., Xue, Q., Hou, Y., Sun, Y., Di, L., Fan, C., Liang, J., Han, Y., Dong, H., Hao, J., & Liu, Z. (2025). Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China. CNS Neuroscience & Therapeutics, 31(2). https://doi.org/10.1111/cns.70237

Vancouver

Qiu Z, Xu F, Zhang M, Yang X, Han Y, Li D, et al. Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China. CNS Neuroscience & Therapeutics. 2025;31(2). doi:10.1111/cns.70237

BibTeX
@article{Qiu2025,
  author = {Qiu, Zhandong and Xu, Fang and Zhang, Mengyao and Yang, Xixi and Han, Yan and Li, Dawei and Liu, Liang and Chen, Jia and Gao, Lehong and Xue, Qing and Hou, Yue and Sun, Ying and Di, Li and Fan, Chunqiu and Liang, Junhua and Han, Yue and Dong, Huiqing and Hao, Junwei and Liu, Zheng},
  title = {Clinical Features of Glutamic Acid Decarboxylase‐65 Neurological Autoimmunity: A Case Series From China},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  volume = {31},
  number = {2},
  doi = {10.1111/cns.70237}
}
Kostenlos starten →